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Abstract
Background: Breast cancer is the most frequent cancer in women and consists of a heterogeneous collection of 
diseases with distinct histopathological, genetic and epigenetic characteristics. In this study, we aimed to identify DNA 
methylation based biomarkers to distinguish patients with locally advanced breast cancer who may benefit from 
neoadjuvant doxorubicin treatment.
Results: We investigated quantitatively the methylation patterns in the promoter regions of 14 genes (ABCB1, ATM, 
BRCA1, CDH3, CDKN2A, CXCR4, ESR1, FBXW7, FOXC1, GSTP1, IGF2, HMLH1, PPP2R2B, and PTEN) in 75 well-described pre-
treatment samples from locally advanced breast cancer and correlated the results to the available clinical and 
molecular parameters. Six normal breast tissues were used as controls and 163 unselected breast cancer cases were 
used to validate associations with histopathological and clinical parameters.
Aberrant methylation was detected in 9 out of the 14 genes including the discovery of methylation at the FOXC1
promoter. Absence of methylation at the ABCB1 promoter correlated with progressive disease during doxorubicin
treatment. Most importantly, the DNA methylation status at the promoters of GSTP1, FOXC1 and ABCB1 correlated
with survival, whereby the combination of methylated genes improved the subdivision with respect to the survival of
the patients. In multivariate analysis GSTP1 and FOXC1 methylation status proved to be independent prognostic
markers associated with survival.
Conclusions: Quantitative DNA methylation profiling is a powerful tool to identify molecular changes associated with 
specific phenotypes. Methylation at the ABCB1 or GSTP1 promoter improved overall survival probably due to prolonged 
availability and activity of the drug in the cell while FOXC1 methylation might be a protective factor against tumour 
invasiveness. FOXC1 proved to be general prognostic factor, while ABCB1 and GSTP1 might be predictive factors for the 
response to and efficacy of doxorubicin treatment. Pharmacoepigenetic effects such as the reported associations in 
this study provide molecular explanations for differential responses to chemotherapy and it might prove valuable to 
take the methylation status of selected genes into account for patient management and treatment decisions.
Background
Breast cancer, the most frequent cancer in women, consists
of a heterogeneous collection of diseases with distinct his-
topathological, genetic and epigenetic characteristics [1].
Conventional single parameters as well as gene expression
signatures have been correlated to breast cancer prognosis.
However, in contrast to endocrine therapy for which estro-
gen receptor expression is a predictive marker of response
to therapy, we so far lack predictive factors for the selection
of a chemotherapeutic regime except for ERBB2 (HER-2)
* Correspondence: tost@cng.fr
1 Laboratory for Epigenetics, Centre National de Génotypage, CEA - Institut de 
Génomique, Evry, France
† Contributed equally
Full list of author information is available at the end of the article© 2010 Dejeux et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Dejeux et al. Molecular Cancer 2010, 9:68
http://www.molecular-cancer.com/content/9/1/68
Page 2 of 13overexpression advocating trastuzumab and increased
anthracycline dosing [2].
While the contribution of genetic factors to breast car-
cinogenesis has long been recognized, it has become evi-
dent that epigenetic changes leading to transcriptional
silencing of tumour suppressor genes are an at least equally
contributing mechanism. In tumours a global loss of DNA
methylation (hypomethylation) of the genome is observed
at early stages of breast carcinogenesis which proceeds with
increasing malignancy [3]. The overall decrease in DNA
methylation is accompanied by a gene-specific increase of
methylation (hypermethylation) of multiple promoter asso-
ciated CpG islands leading to transcriptional silencing of
genes involved in cell cycle arrest as well as apoptosis
[4,5].
The number of genes that has been identified to be aber-
rantly methylated in breast cancer is rapidly growing. Thus,
high-throughput DNA methylation mapping technologies
have the potential to identify distinct methylation signatures
correlating with specific clinical stages and subtypes, but
also to reveal the large heterogeneity of DNA methylation
patterns within a tumour subgroup [6-9]. Considering the
need to improve prognostication in breast cancer in general,
and drug sensitivity prediction in particular [2], the exami-
nation of epigenetic gene alterations may improve our
knowledge about the outcome and the response of a patient
to given treatment.
Recently, we reported the haplotype structure to influence
the level of DNA methylation of the GSTP1 promoter in
breast cancers and to affect patient survival [10]. Here we
broaden our analysis studying the methylation patterns in
the promoter regions of 14 genes in 75 pre-treatment sam-
ples from locally advanced breast cancer by pyrosequenc-
ing. Genes were selected on the following basis: 1. previous
reports of DNA methylation in breast tumours or at least
breast cancer cell lines (ABCB1 [11], ATM [12], BRCA1
[13], CDH3 [14], CDKN2A [13], ESR1 [15], GSTP1 [16],
IGF2 [17], HMLH1 [13], PPP2R2B [18], PTEN [19]) or
other cancers (CXCR4 [20]), 2. genes displaying variation
in breast cancer gene expression profiles (FOXC1 [21]) and
3. tumour suppressor genes known to harbour somatic
mutations or be situated in frequently deleted regions in
breast cancer but for which no DNA methylation analysis
has so far been performed (FBXW7 [22]). In total 432 CpG
positions were investigated resulting in a data set of more
than 37.000 quantitative epigenotypes, confirming previ-
ously reported associations and identifying novel DNA
methylation based biomarkers associated with response to
treatment and survival.
Results
We analyzed promoter methylation at 432 CpGs in 14
genes giving rise to 37.000 epigenotypes (Figure 1A). The
analysis included the DNA methylation in ABCB1 (40
CpGs), ATM (56 CpGs), BRCA1 (46 CpGs), CDH3 (35
CpGs), CDKN2A (30 CpGs), CXCR4 (19 CpGs), ESR1 (50
CpGs) FBXW7 (31 CpGs), FOXC1 (14 CpGs), GSTP1 (21
CpGs), IGF2 (16 CpGs), MLH1 (24 CpGs), PPP2R2B (51
CpGs), and PTEN (39 CpGs). The six normal samples were
unmethylated for all analyzed regions except for the highly
methylated upstream region of BRCA1, the differentially
methylated region of the imprinted IGF2 and the promoter
region of ESR1 (Figure 1A). Three amplification products
in the ABCB1 gene were found to be methylated in 70%,
64% and 81% of the tumours. Methylation was found for
CDKN2A (34% of the samples), FOXC1 (50%), PPP2R2B
(56% and 65%), HMLH1 (14%), PTEN (22% and 76%) and
GSTP1 (65% and 83%). All samples were unmethylated for
the transcription start site of BRCA1, ATM, CDH3, CXCR4
and FBXW7. 10% of the samples exhibited a significant
hypomethylation in the far upstream region of the BRCA1
CpG island. Some methylation was found around the tran-
scription start site for ESR1 but also within the normal
breast samples. None of the genes displayed an age-depen-
dent variation of DNA methylation at the analyzed loci.
Restricting the analysis to the loci with variable DNA
methylation levels, no sample showed a completely normal
methylation profile, 3/75 tumours (4%) showed abnormal
methylation at one locus, 8 (11%) at two loci, 4 (5%) at
three, 14 (19%) at four and five loci, respectively, 16 (21%)
at six, 9 (12%) at seven, 5 (7%) at eight loci and two
tumours (3%) displayed aberrant methylation at nine loci.
On average, five loci were thus aberrantly methylated in
any sample. Methylation events at the different loci were
not randomly distributed and independent from each other
(Figure 1B). As expected, the methylation degrees of the
different regions of the same gene were highly correlated if
methylation was detected in all amplification products.
Less expected, concomitant methylation was often found at
different genes such as the ABCB1, FOXC1, GSTP1,
PPP2R2B, PTEN promoters identifying thus strongly cor-
related methylation events on different chromosomes (Fig-
ure 1B). Methylation at the estrogen receptor promoter did
not correlate with any other gene. Pyrosequencing provides
the advantage of yielding highly quantitative data on con-
secutive CpGs permitting analysis of the homogeneity of
the methylation profiles. We identified for most genes some
"core"-regions where DNA methylation levels correlated
best with molecular and clinical parameters (see below).
For most genes, these regions spanned - as expected - the
transcription start sites.
Correlation to expression profiles
The observed methylation patterns were compared to the
tumour subclasses as defined by microarray expression pro-
filing [21]. Basal-like tumours generally showed a lower
degree of methylation than the other subclasses (luminal A,
luminal B, ERBB2 and normal-like). There was a trend for
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Figure 1 Summary of the methylation data. A) Summary of the average DNA methylation values in percentage for the analysis of the fourteen 
genes (x-axis) in the 75 breast cancer samples, six normal breast tissues (on top) and the six breast cancer cell lines (bottom lines). Absence of meth-
ylation over an amplification product is shown in yellow, complete methylation in dark blue; intermediate methylation degrees by the corresponding 
mixtures of the two colours. B) Nonparametric correlation of methylation levels between genes and between regions within the same gene. The first 
row and the last column contain the gene name or gene name followed by a number that indicate different genomic regions within the same gene 
(Additional File 5). Green squares have been assigned to correlations that are non significant. Red square correlations are significant after FDR correc-
tion (threshold 10%). For each significant correlation 3 values are given from top to bottom: the correlation coefficient (R2 value), the p-value and the 
number of tested samples.
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Page 4 of 13the absence of methylation at ABCB1, FOXC1, PPP2R2B,
and GSTP1 in both the basal-like and normal-like tumours,
while IGF2, MLH1 and PTEN were hypomethylated in the
basal-like tumours but not in the normal-like tumours.
When analyzing the correlation between the expression
level and the DNA methylation status of individual genes,
genes with methylated promoters were almost exclusively
not expressed, while unmethylated genes could be
expressed as well as not be expressed weakening the corre-
lation. The only significant correlation was obtained for
GSTP1 (p = 0.003, Correlation coefficient -0.47). Because
of their association with survival (see below) we analyzed
the expression levels of GSTP1, ABCB1 and FOXC1 by
qRT-PCR (Additional File 1). qRT-PCR analysis correlated
well with the microarray data (GSTP1: Pearson Corr. 0.661,
p = 0.003; FOXC1: Pearson Corr. 0.788, p < 0.001; ABCB1:
Pearson Corr. 0.739, p = 0.015). Consequently a significant
negative correlation between expression as measured by
TaqMan and methylation was found for GSTP1 (Spearman
Correlation -0.567, p = 0.018), while expression and methy-
lation for FOXC1 and ABCB1 were not significantly corre-
lated (p = 0.5 and p = 0.368, respectively). Highly
expressing genes were unmethylated for the respective pro-
moter region of GSTP1 and FOXC1 and methylated pro-
moters correlated with silenced expression. The weak
correlation between expression and DNA methylation for
FOXC1 was due to the fact that the gene was already
silenced in most tumours independent of its methylation
status. Four samples were methylated for ABCB1 but dis-
played high expression. This might be due to alternative
usage of an upstream promoter [23] that is not under the
control of the analyzed CpG island.
Correlation with clinical parameters
Methylation was analyzed in the discovery and validation
cohorts both as a categorical variable, i.e. the presence/
absence of methylation at the respective promoter in associ-
ation with the tumour characteristics, and as a quantitative
variable investigating potential associations between the
extent or the distribution of DNA methylation values and
the analyzed clinical and molecular parameters (Additional
File 2). Promoter methylation of PPP2R2B in the pre-treat-
ment sample was significantly associated with tumour
grade (p = 0.019), whereby high-grade tumours were more
frequently unmethylated than grade 1 and 2 tumours in the
discovery cohort. The same was observed in the validation
cohort of unselected breast cancers (p = 0.008). No associa-
tion between methylation and tumour size was found.
Estrogen receptor status positivity was associated with the
presence and increased extent of methylation at the
PPP2R2B promoter in both the discovery (p = 0.004) and
the validation cohort (p = 0.006). Samples unmethylated for
ABCB1 and those with increased levels of methylation in
the differentially methylated region 2 of IGF2 had more
often overexpression of the ERBB2 oncogene (p = 0.005
and p = 0.007, respectively), previously analyzed by immu-
nohistochemistry [24]. No ERBB2 data was available for
the validation cohort.
Correlation with TP53 mutations
We compared the observed DNA methylation profiles with
the TP53 mutations status and found the lack of ABCB1 and
PPP2R2B methylation to be associated with the presence of
TP53 mutations in the discovery cohort (p = 0.028 and p =
0.010, respectively) as well as in the validation cohort (p =
0.018 and p = 0.001, respectively). Tumours unmethylated
for the middle region of the ABCB1 CpG island were asso-
ciated with mutations in the loop domains L2/L3 (p =
0.022), a region that has previously been shown to be asso-
ciated with lack of response to doxorubicin based treat-
ment. PPP2R2B did not show any differential degree of
methylation in function of the type of TP53 mutation.
Survival analysis and response to treatment in the 
doxorubicin treated cohort
The eight genes displaying variable DNA methylation pat-
terns in a significant number of tumours (ABCB1, BRCA1,
CDKN2A, FOXC1, GSTP1, IGF2, PPP2R2B and PTEN)
within the discovery cohort were tested for association with
survival by a logrank test. Breast cancer specific survival
was significantly improved in patients with methylated pro-
moters for ABCB1, GSTP1 and FOXC1 (p = 0.004, p =
0.004 and p = 0.021 respectively, Figure 2). Methylation of
ABCB1 and GSTP1 did also reach statistical significance
after correction for multiple testing (Bonferroni correction,
uncorrected p < 0.00625). Consistently, absence of methy-
lation (p = 0.0076, Additional File 2) in the CpG island of
ABCB1 was associated with poor response to doxorubicin
(progressive disease) in the patient cohort treated with dox-
orubicin. In the validation cohort treated with different regi-
mens, a significant difference in survival between
methylated and unmethylated samples was confirmed for
FOXC1 (p = 0.024) with patients unmethylated for the pro-
moter region having again worse survival. Methylation of
GSTP1 did not condition improved survival in the valida-
tion cohort of patients (p = 0.331). Similarly, only a trend
for improved survival was observed for the methylation sta-
tus of ABCB1 (p = 0.070). The findings for GSTP1 and
ABCB1 might indicate a treatment specific effect on sur-
vival
Survival analysis in the doxorubicin treated cohort based
on the logrank test indicated that TP53 mutation status (p =
0.001), grade (p = 0.001) and the estrogen receptor status (p
= 0.002) could slightly better differentiate two survival
groups in the analyzed sample collection when compared to
the methylation status of the single genes (ABCB1 (p =
0.004), GSTP1 (p = 0.004) and FOXC1 (p = 0.021)), while
separation based on the progesterone receptor status and
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Figure 2 Kaplan-Meyer plots of overall survival. Kaplan-Meyer plots of overall survival for patients with either methylated or unmethylated GSTP1, 
FOXC1 or ABCB1 promoter, respectively (left column). Increased differentiation of patients is obtained through the use of two gene methylation panels, 
having both genes methylated, either of the two genes methylated and the other one unmethylated or both genes unmethylated (right column). 
The p-value was calculated using a log rank test and are given uncorrected. 'N' is the number of samples in each group. After Bonferroni correction, 
DNA methylation of GSTP1 and ABCB1 as well as GSTP1/ABCB1 and GSTP1/FOXC1 did reach the level of statistical significance. Deaths due to causes not 
related to breast cancer were censored.
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Page 6 of 13amplification of ERBB2 or TOP2A did not reach statistical
significance. However, combination of two of the discov-
ered DNA methylation markers further improved the dis-
tinction between doxorubicin treated patients having two,
one or none of the genes methylated. No statistical differ-
ence on survival in function of the gene was found when
comparing patients that had one of the two genes methy-
lated and these were therefore combined for analysis. The
best two-gene methylation pair comprised GSTP1 and
FOXC1 (p = 8·10-5), followed by GSTP1 and ABCB1 (p =
0.001) and ABCB1 and FOXC1 (p = 0.01). Patients with all
three genes methylated (n = 20) had an improved survival
compared to patients with all three genes unmethylated (n =
10, p = 0.001). However, the separation lost its statistical
significance when patients with mixed methylation patterns
for all three genes were added to the analysis. We investi-
gated if expression could be used as an alternative molecu-
lar measure to DNA methylation and divided samples in
high versus low expression based on the mean expression
values. The expression of GSTP1 was significantly associ-
ated with survival with patients with low levels of expres-
sion having as expected an improved survival (p = 0.048).
FOXC1 (p = 0.247) and ABCB1 (p = 0.181) were not signif-
icant but again showed improved survival for low express-
ing patients. When combining DNA methylation and
expression, patients with an unmethylated GSTP1 promoter
and expressed gene had poorer survival compared to
patients with a methylated promoter that did not express
GSTP1 (p = 0.047). The same correlation was observed for
FOXC1 (p = 0.045) and ABCB1 (p = 0.022).
Cox regression analysis of methylation markers and clinical 
variables in the doxorubicin treated cohort
To identify significant parameters contributing to the
observed differences in survival, Cox regression analysis
was performed. The hazard ratio for each of the contribut-
ing factors was estimated separately (univariate analysis) or
modelled together (multivariate analysis).
Univariate analysis identified the methylation status of
ABCB1, FOXC1 and GSTP1 as significant predictors of
overall survival. Estrogen receptor status as well as TP53
status and grade were also significant predictors of survival
in univariate analysis (Table 1). To investigate if the methy-
lation markers ABCB1, FOXC1 and GSTP1 were indepen-
dent prognostic markers, we performed multivariate
analysis with the methylation markers, grade, estrogen
receptor status, TP53 status and stage. This analysis showed
that the patients in this cohort with unmethylated GSTP1
(HR: 7.52, CI: 1.76-32.07, p = 0.006) and FOXC1 (HR:
7.32, CI: 1.11-48.31, p = 0.039) showed a higher risk of
dying from breast cancer compared with patients methy-
lated for the same genes (Table 2). The effect of ABCB1
methylation on survival was no longer significant in the
multivariate analysis probably due to its association with
other histopathological factors (Additional File 2). Inclu-
sion of the operation status (HR: 2.1, p = 0.452) in the mul-
tivariate analysis did slight reduce the hazard ratio for
GSTP1 (HR: 5.8, p = 0.028) while increasing the HR for
FOXC1 (HR: 8.3, p = 0.03). The HR for the other parame-
ters remained unchanged.
In order to identify the model with the minimum number
of covariates that fitted best the experimental data, we used
the Akaike information criterion. The best model with a
reduced number of covariates explaining survival included
the methylation status of FOXC1 and GSTP1, stage, grade
and estrogen receptor status (Additional File 3A). The best
model with a minimum number of covariates where all
covariates were independent of each other included ER,
grade and the GSTP1 methylation status (Additional File
3B). Using only a single covariate to model the survival of
the patients by the AIC, the methylation status of any of the
three different genes performed superior compared to the
classical parameters with GSTP1 fitting the model best fol-
lowed by FOXC1 and ABCB1. To investigate the effect of
the combination of the methylation status of two genes on
survival, multivariate Cox regression analysis was again
performed. Only the GSTP1/FOXC1 pair (p = 0.005 and p
= 0.013 for the combination of either one or both genes
being unmethylated, respectively) remained significant
together with high grade (p = 0.002) and ER status (p =
0.001) (data not shown).
Discussion
In the presented study we analyzed the methylation patterns
in the promoter regions of fourteen genes in 75 pre-treat-
ment samples from locally advanced breast cancers, six
normal tissues and six widely used cell lines. Aberrant
methylation events were detected in eleven out of the four-
teen genes investigated. Discussion of the negative results
can be found in the Additional File 4. Due to the highly
quantitative nature of the employed pyrosequencing tech-
nology and its limit of detection (~5% methylation in a
sample) all methylation events detected in this study are
occurring in a significant number of cells of a tumour sam-
ple and are therefore likely to have an impact on the charac-
teristics of the tumour and - as pre-treatment samples were
analyzed - might influence the response to a given chemo-
therapy.
The identified methylation patterns were non-random and
some of the genes displayed a significant degree of co-
methylation pointing to a common epigenetic mechanism
for their inactivation during tumourigenesis. There was a
tendency for a lower frequency of aberrant promoter meth-
ylation in basal- and normal-like tumour samples. In a
study recently published, basal-like tumour cell lines were
characterized by the concomitant hypermethylation of a six
gene panel (CDH1, CEACAM6, CST6, ESR1, LCN2,
SCNN1A) [25]. However, using methylation in repetitive
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methylation levels, basal-like breast tumours are character-
ized by an overall loss of methylation (J. Tost, unpub-
lished). The observed hypomethylation in the far upstream
region of BRCA1 (green squares for BRCA1_1 in Figure
1A) was found mainly in estrogen receptor negative
tumours like the basal-like tumours further supporting the
hypothesis that the genome-wide hypomethylation
observed in breast cancer (as well as in any other cancer
types) might be more pronounced in this tumour subclass.
We did not detect hypermethylation of the BRCA1 promoter
(Amplicons BRCA1_2 and BRCA1_3 in Figure 1A), which
might be explained by the absence of the rare metaplastic
subtype of basal-like breast cancers, to which most methy-
lation events of BRCA1 seem to be restricted [26].
Since the tumour sub-classification based on gene expres-
sion is driven to a significant extent by expression of the
estrogen receptor (ESR1), we studied its promoter methyla-
tion in normal samples as well as in a subset of the tumours.
It has previously been shown that its degree of DNA methy-
lation did not correlate well with hormone receptor status
[27]. Our data confirms recently published data showing a
certain degree of methylation of the estrogen receptor in
tumours as well as in peritumoural/normal tissue but no dif-
ference in the quantitative distribution between normal and
tumoural tissue [28].
Another studied gene,PPP2R2B on 5q31-q32 encodes the
regulatory subunit of the protein phosphates 2A complex
(PP2A) and has been proposed as a tumour suppressor gene
candidate due to its negative control of cell growth and the
high frequency of LOH in breast cancers [29]. An associa-
tion of methylation levels to TP53 mutation status is
reported here for the first time and might provide an alter-
native molecular mechanism for gene inactivation, as also
the LOH has previously been associated with TP53 muta-
tions [30]. The previously observed association with hor-
mone receptor status [18] was also confirmed in our study.
Table 1: Univariate survival analysis
Univariate
Covariate Baseline Coefficient HR 95,0% CI for HR p-value
Grade 2 Grade 1 2.047 7.742 (1.012-59.228) 0.049
Grade 3 Grade 1 2.955 19.193 (2.455-150.003) 0.005
T3 T2 -0.18 0.982 (0.128-7.517) 0.986
T4 T2 0.569 1.767 (0.228-13.717) 0.586
N1 N0 0.696 2.007 (0.696-5.783) 0.197
N2 N0 0.759 2.136 (0.714-6.383) 0.174
M M0 0.606 1.833 (0.683-4.918) 0.229
Stage 3 Stage2 0.852 2.344 (0.686-8.008) 0.174
Stage 4 Stage2 1.088 2.970 (0.708-12.463) 0.137
ER ER positive 1.335 3.800 (1.566-9.223) 0.003
PR PR positive 0.620 1.859 (0.800-4.318 0.149
ErbB2 ErbB2 positive 0.965 2.624 (0.931-7.395) 0.068
TP53 Wild type TP53 1.230 3.423 (1.553-7.542) 0.002
ABCB1_2 ABCB1_2 
Methylated
1.147 3.147 (1.389-7.133) 0.006
FOXC1_3 FOXC1_3 
Methylated
1.030 2.802 (1.127-6.969) 0.027
GSTP1_2 GSTP1_2 
Methylated
1.215 3.369 (1.280-8.868) 0.014
Univariate survival analysis using the Cox regression model using the categorical methylation data. Positive hazard ratios indicate an 
increased risk of dying from breast cancer and are calculated for the different covariates in reference to the baseline as given in the 2nd 
column.
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Our study is the first to show DNA methylation of the
ABCB1 CpG island to be associated with ERBB2 amplifica-
tion, TP53 mutation status, and response to doxorubicin
treatment and overall survival in a doxorubicin-exposed
cohort of primary breast cancers. Although the number of
patients with progressive disease in the current study is lim-
ited and requires confirmation in other patient cohorts
treated with anthracycline based treatment, there is good
evidence that methylation of ABCB1 plays an important
role in the response to doxorubicin. Lack of methylation in
the central part of the ABCB1 CpG island was found to be
associated with the TP53 mutation status and in particular
with mutations in the L2/L3 DNA binding domain which
have previously been associated with lack of response to
treatment in the same patient cohort [24]. This finding fur-
ther substantiates previous evidence indicating a link
between TP53 and ABCB1 [31]. How much this association
contributes to the resistance to doxorubicin observed in
some breast cancer patients needs further investigation.
Expression of ABCB1 has been shown to reduce intracellu-
lar doxorubicin concentration in cell cultures [32] and re-
expression and promoter demethylation has been associated
with resistance to anticancer drugs in vitro [33]. Although
evidence from in vivo studies has been conflicting [34], a
recent mouse model study lends support to the findings of
our study by demonstrating that an increase of ABCB1
expression the mice leads to the development of doxorubi-
cin resistance that might be reversed by ABCB1 inhibitors
such as tariquidar [35].
Methylation and ERBB2 overexpression
A possible link between ERBB2 and ABCB1 expression
has been observed in a multidrug resistant MCF-7 cell line
[36]. The amplification of the topoisomerase IIα (TOP2A)
gene significantly improves the outcome of anthracycline
based adjuvant chemotherapy [37,38]. Interestingly,
TOP2A and ERBB2 are co-amplified in our dataset (p =
0.008, results not shown) warranting further investigation
to explore the interaction between ABCB1 methylation sta-
tus and TOP2A/ERBB2 amplification and how the com-
bined effect of these proteins contributes to the drug
resistance observed in anthracycline treatment regimens.
IGF2 exerts its action on cellular growth through the
insulin-like growth factor 1 receptor which interferes with
anti-ERBB2 treatment through Akt signalling [39]. In
murine cancer models methylation changes in the differen-
tially methylated region 2 of IGF2 have been associated
with overexpression of IGF2 [40], which in turn might acti-
vate IGF1R signalling and increase cell growth. Here we
Table 2: Multivariate survival analysis
Multivariate
Covariate Baseline Coefficient(bi) HR(exp(bi) 95,0% CI for 
Exp(B)
p-value
Grade 2 Grade1 1,67 5,30 (0,52-53,75) 0,159
Grade 3 Grade1 3,45 31,65 (2,47-404,27) 0,008
ER ER positive 2,59 13,39 (2,62-68,50) 0,002
TP53 TP53 wild type 1,75 5,73 (1,11-29,40) 0,036
Stage 3 Stage2 0,19 1,21 (0,20-7,03) 0,833
Stage 4 Stage2 2,00 7,38 (1,12-48,55) 0,038
ABCB1_2 Methylated 
ABCB1_2
-1,13 0,32 (0,05-2,20) 0,247
FOXC1_3 Methylated 
FOXC1_3
1,99 7,32 (1,11-48,31) 0,039
GSTP1_2 Methylated 
GSTP1_2
2,02 7,52 (1,76-32,07) 0,006
Multivariate survival analysis using the Cox regression model using the categorical methylation data. Positive hazard ratios indicate an 
increased risk of dying from breast cancer and are calculated for the different covariates in reference to the baseline as given in the 2nd 
column.
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cifically observed in ERBB2 positive breast cancers provid-
ing a new potential mechanistic link between IGF1R
expression and ERBB2 status via IGF2 methylation status.
Methylation and survival
We identify here the GSTP1 and FOXC1 methylation status
as independent prognostic markers for breast cancer sur-
vival in a uniform patient cohort receiving neoadjuvant
doxorubicin monotherapy prior to surgery and five years of
tamoxifen for all ER positive patients according to a clini-
cal study protocol [24]. FOXC1 methylation status might be
a general prognostic marker as it is able to separate patients
in good and poor survival groups in the doxorubicin treated
as well as in validation cohort while GSTP1 and ABCB1
methylation status might be a predictive marker for doxoru-
bicin monotherapy as the methylation status of these genes
were not able to separate patients into survival groups in the
validation cohort [2]. This is further supported by the fact
that the hazard ratio for GSTP1 methylation decreased
when the operation status was taken into account indicating
that those tumours that increased further or at least did not
regress during neoadjuvant treatment were more often unm-
ethylated for GSTP1 while FOXC1 hazard ratio increased
as would be expected for a treatment independent effect.
ABCB1 methylation status proved to be a marker for sur-
vival in the discovery cohort although it was not indepen-
dent of other known markers in a multivariate model. The
association with survival was less significant when the
expression status instead of the DNA methylation status
was analysed due to a strong correlation between DNA
methylation and expression for GSTP1 only.
We confirm here a very recent report on the presence and
extent of DNA methylation in the promoter of FOXC1, a
member of the forkhead protein family, many members of
which are involved in the development and progression of
cancer [41]. Mutations in FOXC1 have recently been
reported in a candidate re-sequencing approach of breast
tumours [42] and FOXC1 was found to be specifically
hypomethylated and highly expressed in CD44+ compared
to CD24+ stem cell progenitors, but no data correlating sur-
vival to the methylation patterns was presented [43]. The
overexpression of the closely related FOXC2 gene has been
found to promote tumour metastasis and invasiveness [44].
CpG hypermethylation of the promoter region of the glu-
tathione-S-transferase 1 (GSTP1) is a well established bio-
marker for hormone dependent cancers. Low activity of
GSTP1 resulting from promoter hypermethylation may
increase the effective therapeutic dose of the pharmacologi-
cal agent due to lower conjugation and inactivation of the
drug leading to increased survival. In support of this
hypothesis it has been shown that GSTP1 expression corre-
lates with doxorubicin resistance in breast cancer cell lines
[45]. The observed improved survival has very recently
been shown in samples in concordance with previous
reports where the absence of GSTP1 protein expression
correlated with improved survival in invasive breast cancer
samples [46,47].
Conclusions
Methylation at the ABCB1 or GSTP1 promoter improved
overall survival probably due to prolonged availability and
activity of the drug in the cell while FOXC1 methylation
might be a protective factor against tumour invasiveness.
The FOXC1 methylation status might be a widely appli-
cable prognostic factor for breast cancer patients while the
methylation status of ABCB1 and GSTP1 might be a predic-
tive factor for doxorubicin and perhaps anthracycline treat-
ment in general. However, further studies are necessary to
confirm the predictive value of these markers requiring
additional patient cohorts treated with a doxorubicin/
anthracycline based monotherapy. Valuable time for treat-
ment might be gained and the serious side-effects of a dox-
orubicin based regimen might be avoided taking the
methylation status for treatment decisions into account. As
the analyzed cohort consists of locally advanced primary
tumours, it will be interesting to investigate the DNA meth-
ylation profiles also in T1/T2 and early stage breast cancer
samples. Despite similar RNA expression profiles [21],
some biological differences such as different frequencies of
polymorphic alleles have recently been found to be
enriched in advanced tumours [48]. Additional studies
including prospective trials are required to fully evaluate
the potential of these promising DNA methylation based
markers to predict and monitor the efficacy of chemother-
apy and to measure their impact on breast cancer manage-
ment.
Methods
Patient cohorts
Discovery cohort (Doxorubicin treated)
Locally advanced breast cancer patients, admitted to the
Haukeland University Hospital in Bergen (Norway)
between 1991 and 1998 were part of a prospective study
evaluating predictive factors for response to doxorubicin (n
= 94). Tumour DNA was available in sufficient quantity to
perform methylation analyses from 75 of the patients. Tis-
sue was obtained by an incisional biopsy prior to therapy
and was immediately snap-frozen (liquid nitrogen in the
theater) as previously reported [24]. DNA was isolated
from snap frozen tumour tissue using phenol/chloroform
extraction. The primary treatment consisted of weekly dox-
orubicin treatment (14 mg/m2) scheduled for 16 weeks.
Patients with an operable tumour (n = 60) after neoadjuvant
treatment had surgery followed by radiotherapy immedi-
ately after termination of the neoadjuvant chemotherapy.
Eight patients had to be given radiotherapy prior to surgery
due to local tumour extension, and seven patients were not
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Women with estrogen and/or progesterone positive tumours
were all treated with tamoxifen (30 mg daily for 5 years).
The main clinical characteristics of the analyzed 75 samples
are given in Table 3. The study protocol was approved by
the local ethical committee, and the patients gave their
informed consent.
Validation cohort
163 random, unselected breast cancer samples were used
for the validation of the observed associations with clinico-
pathological factors. Clinical and molecular parameters
such as histological grade (n = 162), Estrogen receptor sta-
tus (n = 158) and TP53 mutation status (n = 162) were
available and used for validation. Follow-up/survival data
was available for 87 of the patients. Tumour DNA extrac-
tion, bisulphite treatment and pyrosequencing analyses was
performed using the same procedures as for the discovery
dataset.
Normal material
DNA samples from normal breast tissue were included as
control samples for methylation analysis. Normal breast tis-
sue (n = 6) was obtained from women who underwent a
biopsy of the mammary gland because of mammographic
abnormalities, but for which histology confirmed the pres-
ence of only normal tissue.
Cell lines
The sample set was completed by immortalized human
mammary epithelial cells (HMEC) and five widely used
breast cancer cell lines (BT474, MCF-7, MDA-MB-231,
SK-BR-3, and T47D).
TP53 mutation, copy number and expression analyses
Mutations in TP53 were analyzed in both the discovery and
the validation cohorts by temporal temperature gradient
electrophoresis (TTGE) followed by Sanger sequencing as
previously described with primers covering regions (exons
and introns) from exon 2-11 [24,49]. 50 of the doxorubicin
treated tumours have been analyzed for gene expression
using genome wide cDNA microarrays [21], and a subset of
these tumours was analyzed for copy number alterations
[50].
Methylation assays
Assays were optimized on unmethylated and methylated
DNA as previously described [51]. DNA concentrations
were determined using the Quant-iT™ dsDNA broad range
assay kit (Invitrogen, Cergy Pontoise, France) and normal-
ized to a concentration of 50 ng/μl. One μg of DNA was
bisulphite converted using the MethylEasy™ HT Kit for
Centrifuge (Human Genetic Signatures, North Ryde, Aus-
tralia) according to the manufacturer's instructions. Quanti-
tative DNA methylation analysis of the bisulphite treated
DNA was performed by pyrosequencing or - in case of sev-
eral sequencing primers - by serial pyrosequencing [51].
Table 3: Molecular and clinical characteristics of the 
analyzed sample cohort
Clinicopathological factors Number of samples
Median age at diagnosis 65 (range 32-85)
Histological grade
Grade 1 18 (24%)
Grade 2 38 (50.7%)
Grade 3 19 (25.3%)
Response
Progressive Disease 7 (9.5%)
PR, MC or SD 67 (90.5%)
Tumor size
T2 3 (4%)
T3 47 (62.7%)
T4 25 (33.3%)
Lymph node metastasis
N0 25 (33.3%)
N1 29 (38.7%)
N2 21 (28%)
Distant metastasis
M0 66 (88.0%)
M1 9 (12%)
Stage
Stage 2 18 (24%)
Stage 3 46 (61%)
Stage 4 11 (15%)
TP53 mutations
Wild type 55 (73.3%)
Mutant 20 (26.7%)
Estrogen receptor status
Positive 65 (86.7%)
Negative 10 (13.3%)
Progesteron receptor 
status
Positive 58 (77.3%)
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treated human genomic DNA and 5 to 7.5 pmol of forward
and reverse primer, one of them being biotinylated. Oligo-
nucleotides for PCR amplification and pyrosequencing
(Additional File 5) were synthesized by Biotez (Buch, Ger-
many). Reaction conditions were 1× HotStar Taq buffer
supplemented with 1.6 mM MgCl2, 100 μM dNTPs and 2.0
U HotStar Taq polymerase (Qiagen, Courtaboeuf, France)
in a 25 μl volume. The PCR program consisted of a dena-
turing step of 15 min at 95°C followed by 50 cycles of 30 s
at 95°C, 30 s at the respective annealing temperature (Addi-
tional File 1) and 20 s at 72°C, with a final extension of 5
min at 72°C. 10 μl of PCR product were rendered single-
stranded as previously described [51] and 4 pmol of the
respective sequencing primer (Additional File 1) were used
for analysis. Quantitative DNA methylation analysis was
carried out on a PSQ 96MD system with the PyroGold SQA
Reagent Kit (Pyrosequencing) and results were analyzed
using the Q-CpG software (V.1.0.9, Pyrosequencing AB).
Expression analysis
50 of the tumours have previously been analyzed for gene
expression using genome wide cDNA microarrays [21]. For
quantitative RT-PCR based expression analysis (TaqMan),
cDNA was synthesized from 1 μg of total RNA with ran-
dom hexamers using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, Ca) in
a final volume of 10 μl. Real-time PCR reactions were per-
formed in triplicate in a final volume of 10 μl using 50 ng of
cDNA and the TaqMan® Gene Expression Master Mix
(Applied Biosystems). TaqMan assays were all purchased
from Applied Biosystems: Hs 00943351_g1 (GSTP1),
Hs00184500_m1 (ABCB1) and Hs00559473_s1 (FOXC1).
Human Breast Total RNA (Ambion, Austin, TX) was used
to generate standard curves. PMM1 (Hs00963626_m1) was
used as endogenous control and the relative gene expres-
sion levels were determined using the standard curve
method and normalized to PMM1.
Statistical analysis
Differences in the presence of methylation were determined
by a two-sided Fisher's test and χ2 tests. Samples were
scored as methylated when the methylation degree
exceeded the average methylation degree of the normal
samples by two times the standard deviation of the normal
samples and had at least a methylation degree of 5% (detec-
tion limit of the technology). Odds ratio and 95% confi-
dence intervals were calculated. Differences in the
distribution of methylation were assessed by the non-para-
metric Mann-Whitney or the Kruskal-Wallis test. Correla-
tion between the methylation status of the different genes
was calculated by the non-parametric Kendall's tau test.
Pearson's coefficients were used to study the correlation
between methylation and expression levels. All calculations
were performed using Statistical Package for Science ver-
sion 15.0. The Cox proportional hazards model was used to
evaluate the effect sizes (given as hazard ratios), 95% Con-
fidence intervals (CI), regression coefficients and statistical
significance of known clinicopathological features as well
as the methylation status of selected genes. All covariates
were treated as categorical variables. To investigate the
relationship between multiple explanatory factors and sur-
vival, we used the Akaike information criterion (AIC) [52].
AIC evaluates the suitability of a selection of covariates in
order to model the experimental observation and adds a
penalty score with increasing number of parameters
included in the model. The model with the minimum AIC is
thus the model describing best the survival data. All possi-
ble combinations with respect to grade, stage, ER and TP53
mutation status as well as methylation of ABCB1, FOXC1
and GSTP1 respectively, were considered as covariates to
the model. With L being the likelihood function of the
model and k indicating the number of parameters of the
model, the Akaike information criterion (AIC) is calculated
by: AIC = -2log L+2k.
Additional material
Additional file 1 Correlation between DNA methylation and RNA 
expression for GSTP1, FOXC1 and ABCB1. Scatter plots showing the cor-
relation between DNA methylation and RNA expression as measured by 
TaqMan for GSTP1, FOXC1 and ABCB1.
Negative 17 (22.7%)
ErbB2 receptor status
Positive 11 (25%)
Negative 33 (75%)
Survival
> 5 years 20 (26.7%)
< 5 years 55 (73.3%)
PR: partial response; MC: minimal change; SD: stable disease. 
Lymph node status was assessed clinically prior to neoadjuvant 
therapy and does not necessarily correspond to pathological 
lymph node status. In this context N0 means that no enlarged 
nodes were felt prior to therapy. N1 corresponds to the presence 
of palpable and movable ipsilateral axillary lymph nodes 
suspicious of the presence of metastases while N2 corresponds 
to fixed ipsilateral axillary lymph nodes and thus very likely to the 
presence of tumours.
Table 3: Molecular and clinical characteristics of the 
analyzed sample cohort (Continued)
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